Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Design, Rationale, and Methods of the INITIATE-HFrEF Trial | Synapse

February 8, 2026JACC Advances0 citationsOpen Access

Ver artículo completo

Design, Rationale, and Methods of the INITIATE-HFrEF Trial

JFJoão Pedro Ferreira AOA. Simões Oliveira FSF S Saraiva

Puntos clave

To determine whether simultaneous initiation of ARNi and SGLT2i is noninferior to sequential initiation in patients with HFrEF.
Conducted as a randomized trial.
Participants include patients with heart failure with reduced ejection fraction (HFrEF).
Interventions involve simultaneous versus sequential initiation of ARNi and SGLT2i.
Outcomes assessed include treatment effectiveness and heart failure management efficiency.
The trial aims to show that simultaneous initiation does not lead to worse outcomes than sequential initiation.
Expected findings will clarify optimal treatment strategies for HFrEF.

Resumen

Initiation of ARNi and SGLT2i in Patients With HFrEF is a randomized trial to test whether a simultaneous initiation of ARNi and SGLT2i is noninferior to a sequential initiation of one agent followed by the other 4 to 12 weeks apart.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Ferreira et al. (Sun,) studied this question.

synapsesocial.com/papers/6988270a0fc35cd7a8845df9 https://doi.org/https://doi.org/10.1016/j.jacadv.2026.102589